{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:22:33Z","timestamp":1778682153126,"version":"3.51.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1093\/carcin\/bgr278","type":"journal-article","created":{"date-parts":[[2011,11,26]],"date-time":"2011-11-26T01:13:23Z","timestamp":1322270003000},"page":"285-293","source":"Crossref","is-referenced-by-count":22,"title":["Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model"],"prefix":"10.1093","volume":"33","author":[{"given":"Hongfeng","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mendel","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,11,24]]},"reference":[{"key":"key\n\t\t\t\t20170521001929_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"key\n\t\t\t\t20170521001929_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol."},{"key":"key\n\t\t\t\t20170521001929_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2402889","article-title":"Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back","volume":"17","author":"von Bubnoff","year":"2003","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170521001929_bib4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"key\n\t\t\t\t20170521001929_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170521001929_bib6","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170521001929_bib7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"key\n\t\t\t\t20170521001929_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170521001929_bib9","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","article-title":"Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)","volume":"108","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170521001929_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"key\n\t\t\t\t20170521001929_bib11","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"key\n\t\t\t\t20170521001929_bib12","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"key\n\t\t\t\t20170521001929_bib13","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","article-title":"BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia","volume":"285","author":"Yuan","year":"2010","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170521001929_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrc1526","article-title":"Aurora-A\u2014a guardian of poles","volume":"5","author":"Marumoto","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"key\n\t\t\t\t20170521001929_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc1502","article-title":"Aurora-kinase inhibitors as anticancer agents","volume":"4","author":"Keen","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"key\n\t\t\t\t20170521001929_bib16","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1093\/emboj\/17.11.3052","article-title":"A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers","volume":"17","author":"Bischoff","year":"1998","journal-title":"EMBO J."},{"key":"key\n\t\t\t\t20170521001929_bib17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/2496","article-title":"Tumour amplified kinase STK15\/BTAK induces centrosome amplification, aneuploidy and transformation","volume":"20","author":"Zhou","year":"1998","journal-title":"Nat. Genet."},{"key":"key\n\t\t\t\t20170521001929_bib18","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1073\/pnas.202606599","article-title":"Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A","volume":"99","author":"Littlepage","year":"2002","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key\n\t\t\t\t20170521001929_bib19","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1038\/onc.2008.76","article-title":"Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice","volume":"27","author":"Zhang","year":"2008","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t20170521001929_bib20","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1038\/sj.onc.1209707","article-title":"Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation","volume":"25","author":"Wang","year":"2006","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t20170521001929_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1535-6108(02)00235-0","article-title":"AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol","volume":"3","author":"Anand","year":"2003","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170521001929_bib22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","article-title":"VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo","volume":"10","author":"Harrington","year":"2004","journal-title":"Nat. Med."},{"key":"key\n\t\t\t\t20170521001929_bib23","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key\n\t\t\t\t20170521001929_bib24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","article-title":"Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680","volume":"66","author":"Young","year":"2006","journal-title":"Cancer Res."},{"key":"key\n\t\t\t\t20170521001929_bib25","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1128\/MCB.22.3.874-885.2002","article-title":"Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases","volume":"22","author":"Crosio","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"key\n\t\t\t\t20170521001929_bib26","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1242\/jcs.01418","article-title":"Requirements for the destruction of human Aurora-A","volume":"117","author":"Crane","year":"2004","journal-title":"J. Cell Sci."},{"key":"key\n\t\t\t\t20170521001929_bib27","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1101\/gad.1007302","article-title":"Identification of a new APC\/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit","volume":"16","author":"Littlepage","year":"2002","journal-title":"Genes Dev."},{"key":"key\n\t\t\t\t20170521001929_bib28","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow","volume":"92","author":"Pear","year":"1998","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170521001929_bib29","first-page":"970","article-title":"Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells","volume":"1","author":"Kirschner","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"key\n\t\t\t\t20170521001929_bib30","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1021\/jm9000314","article-title":"A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B","volume":"52","author":"Aliagas-Martin","year":"2009","journal-title":"J. Med. Chem."},{"key":"key\n\t\t\t\t20170521001929_bib31","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170521001929_bib32","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-08-0721","article-title":"Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells","volume":"14","author":"Fiskus","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"key\n\t\t\t\t20170521001929_bib33","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bcp.2009.10.009","article-title":"Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia","volume":"79","author":"Donato","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"key\n\t\t\t\t20170521001929_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11899-011-0079-9","article-title":"New drugs for chronic myelogenous leukemia","volume":"6","author":"Santos","year":"2011","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"key\n\t\t\t\t20170521001929_bib35","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1073\/pnas.0608798104","article-title":"Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase","volume":"104","author":"Manfredi","year":"2007","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key\n\t\t\t\t20170521001929_bib36","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.bmcl.2010.04.119","article-title":"3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors","volume":"20","author":"Ando","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"key\n\t\t\t\t20170521001929_bib37","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1111\/j.1582-4934.2010.01218.x","article-title":"The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib","volume":"15","author":"Kelly","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"key\n\t\t\t\t20170521001929_bib38","doi-asserted-by":"crossref","first-page":"31785","DOI":"10.1074\/jbc.M805880200","article-title":"Aurora A is essential for early embryonic development and tumor suppression","volume":"283","author":"Lu","year":"2008","journal-title":"J. Biol. Chem."}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/33\/2\/285\/17290614\/bgr278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T01:24:17Z","timestamp":1593307457000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article-lookup\/doi\/10.1093\/carcin\/bgr278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,24]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,11,24]]},"published-print":{"date-parts":[[2012,2]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgr278","relation":{},"ISSN":["1460-2180","0143-3334"],"issn-type":[{"value":"1460-2180","type":"electronic"},{"value":"0143-3334","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11,24]]}}}